Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Public ClinicalTrials.gov record NCT06841705. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Early Concomitant Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Study identification
- NCT ID
- NCT06841705
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Shilpa Grover, MD, MPH
- Other
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Vedolizumab 300 MG Injection [Entyvio] Drug
- Prednisone (and methylprednisolone) Drug
- Prednisone Taper Drug
- Placebo Prednisone Capsules Other
- Placebo Vedolizumab Other
- Sulfamethoxazole-Trimethoprim Other
- Placebo for Sulfamethoxazole-Trimethoprim Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2025
- Primary completion
- Jul 29, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Nov 3, 2025
2025 – 2026
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06841705, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2025 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06841705 live on ClinicalTrials.gov.